Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049391 | 0.85 | ERCC1 (0.64) | MEP1AMEP1BERCC1ERCC4HPGD | |
| SCHEMBL5036231 | 0.85 | CNR1 (0.61) | MTNR1AMTNR1BCNR1GAARAB9A | |
| SCHEMBL12720885 | 0.85 | SPR (0.67) | MTNR1AMTNR1BCNR1GAARAB9A | |
| SCHEMBL19002549 | 0.85 | CNR1 (0.55) | MTNR1AMTNR1BCNR1GAARAB9A | |
| SCHEMBL2007111 | 0.84 | CNR1 (0.62) | MTNR1AMTNR1BCNR1GAARAB9A | |
| SCHEMBL19049570 | 0.82 | CNR1 (0.61) | CNR1GAARAB9AMEP1AMEP1B | |
| SCHEMBL4775980 | 0.82 | ACACB (0.63) | MTNR1AMTNR1BCNR1RAB9AACACB | |
| SCHEMBL19002632 | 0.82 | CNR1 (0.57) | CNR1GAARAB9AMEP1AMEP1B | |
| SCHEMBL19002540 | 0.79 | SPR (0.71) | MTNR1AMTNR1B | |
| SCHEMBL26079448 | 0.79 | MTNR1A (0.68) | MTNR1AMTNR1BCNR1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MTNR1A 1704/4885MTNR1B 1599/4885CNR1 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.